GeneHarbor focuses on the development and manufacture of innovative biotech products, enzymes in particular, and enzymatic production of various highly value-added products.

Enzymes or bio-catalysis are responsible for the most metabolic activities in any living organisms. Enzyme based process, one of the most dynamic sectors of biotechnology, is a greener and more efficient industrial manufacture practice alternative to conventional chemical or fermentation processes.

At present, three major obstacles prevent the enzymatic process from wider industrial applications (1) high cost of the enzymes; (2) high cost of the coenzyme (ATP, NADH, NADPH, etc); and (3) lack of robust process tailored for industrial production. We at GeneHarbor have committed over 15 years of intensive R&D to address the above challenges. We have developed a series of platform technologies that significantly reduce the cost of the enzymes and coenzymes required and make the enzymatic manufacture of many biochemicals possible. We have, at industrial scale, established commercial viable production of glutathione (GSH); S-adenosylmethione (SAMe); Nicotinamide adenine dinucleotide (NAD) and Nicotinamide mononucleotide (NMN). We believe that GHs technology is now ready for low cost production of highest quality of many more complicated biochemicals. We are currently exploring its application in enzymatic production of APIs and low cost of monoclonal/polyclonal purifications.

The Company also operates its own manufacture facility that industrially manufactures biochemicals of the highest standard. The products and product pipeline include: reduced glutathione; NAD, NADH, NADP, NADPH, NMN, protein A, protein G, protein L, protein A affinity column, protein G affinity column, and protein L affinity column.

The mother of the Company, incorporated in Bermuda in 2004, is devoted to design, development and deploy innovative, enzyme-based, cost-effective manufacture processes for the production of diversified industrial products. We have concentrated its efforts and resources on building up reservoirs for cutting edge proprietary technologies and dedicated talents, and has  invented  an enabling  comprehensive biotechnology platform Immobilized Enzyme Assembly for Cascade Biocatalysis. Applying the proprietary technology, we have established over a dozen of novel processes for low-cost production of high quality pharmaceutical, nutraceutical and food products including glutathione, trehalose, co-enzyme I (NAD/NADH), nicotinamide mononucleotide (NMN) co-enzyme II (NADP/NADPH), s-adenosylmethione, phosphocreactine, coenzyme A and three major antibiotics intermediates/API.  The technologies and the industrial processes have been validated by multiple market acceptance, including the products manufactured using the technology and over dozen commercial deals in the form of collaborative agreements, substantial milestone payments and technology licensing with industrial leaders in the field.   

 

GeneHarbor is unique: [1] we are the very few, if any, of the enzyme companies in the world that has a complete chain of industrial enzyme production, and with world-leading technology in most of the steps.  The key technology competence makes GH uniquely qualified for commercially-viable production of many invaluable products; [2] our primary focus is not to improve the existing enzyme products, rather, we explore novel enzymes and create previously non-existing markets that reply upon our technology; and [3] we are working on a number of pipeline products, each of them has multi-billion  market potential.

The company has its headquarter and R & D centre located at Hong Kong Science Park and a pilot manufacture facility stationed in Shanghai, with a large production facility under construction in Changshu, Suzhou and another large  production facility in planning.